Tempus targets 100,000 whole genomes for AI

Tempus said it is building a research platform with 100,000 disease-specific whole-genome sequences linked to longitudinal clinical outcomes, with a long-term goal of 1 million genomes, according to the company’s September 11 announcement carried by Business Wire. Initial access is through an Early Adopter Program and general availability is planned for mid-2027, so the headline is a future data supply rather than a ready-made clinical model. Our Tempus cardiology funding analysis is the relevant boundary: health-AI builders should treat the genome plan as a dataset-access and validation opportunity, not evidence that clinical authorization or outcome lift has arrived.